Multicentre trials: a US regulatory perspective.
Multicentre trials are very common in the field of drug development. In recent years, multicentre trials have taken on a multinational and multiregional aspect. We provide a conceptual framework for the use of multicentre trials in the context of drug development, from the perspective of drug regulation in the United States. In this paper, we review some regulatory history, milestones and standards as they relate to multicentre trials. Special attention is given to the similarities and differences in the approaches to multicentre trials in the following documents; Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, International Conference on Harmonization, Draft Guideline on Statistical Principles for clinical trials and the Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biologic Products. The paper includes a consideration of some of the issues in the analysis of data from multicentre trials.
Anello
Charles
C
Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, USA. charles.anello@fda.hhs.gov
O'Neill
Robert T
RT
Dubey
Satya
S
D017277:Drug Approval; D049673:History, 20th Century; D015337:Multicenter Studies as Topic / Q000266:history / Q000331:legislation & jurisprudence* / Q000592:standards / Q000706:statistics & numerical data; D014481:United States; D014486:United States Food and Drug Administration